Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection
Authors:
Open Access
- 1 January 2000
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 31 (1) , 201-206
Abstract
Liver toxicity is a common side effect of antituberculosis (anti-TB) drugs. We studied the differences in liver dysfunction observed during anti-TB treatment between hepatitis B virus carriers (HBV) and noncarriers. Three hundred twenty-four patients on anti-TB drugs were recruited and followed up for 1 year. Forty-three patients with HBV and 276 non-HBV patients were included for analysis. Liver function tests and viral markers were monitored monthly. Liver biopsy was requested whenever the alanine transaminase (ALT) was persistently abnormal. Eighty-six HBV carriers who were not given anti-TB drugs were chosen as a second control and evaluated prospectively. The incidence of liver dysfunction was significantly higher in HBV carriers given anti-TB drugs (34.9%) when compared to noncarriers (9.4%, P < .001) and with HBV carriers not given anti-TB drugs (8.1%, P < .001). For patients given anti-TB drugs, HBV carriers who developed liver dysfunction were younger (P = .011) and had more severe liver injury compared with noncarriers (P = .008). By multiple logistic regression analysis, age (P = .002) and hepatitis B infection (P < .001) were the only 2 significant risk factors for hepatotoxicity related to anti-TB therapy.Keywords
This publication has 18 references indexed in Scilit:
- A prospective clinical study of isoniazid‐rifampicin‐pyrazinamide‐induced liver injury in an area endemic for hepatitis BJournal of Gastroenterology and Hepatology, 1997
- Anti-tuberculosis medication and the liver: dangers and recommendations in managementEuropean Respiratory Journal, 1995
- Histological grading and staging of chronic hepatitisJournal of Hepatology, 1995
- Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazidHepatology, 1995
- Quantitative detection of hepatitis C virus RNA with a solid-phase signal amplification method: Definition of optimal conditions for specimen collection and clinical application in interferon-treated patientsHepatology, 1994
- Significance of serum hepatitis C virus RNA levels in chronic hepatitis CThe Lancet, 1993
- Controlled Trial of 2, 4, and 6 Months of Pyrazinamide in 6-Month, Three-Times-Weekly Regimens for Smear-positive Pulmonary Tuberculosis, Including an Assessment of a Combined Preparation of Isoniazid, Rifampin, and Pyrazinamide: Results at 30 MonthsAmerican Review of Respiratory Disease, 1991
- Toxic Hepatitis with Isoniazid and RifampinChest, 1991
- Isoniazid-rifampin-induced hepatitis in hepatitis B carriersGastroenterology, 1990
- RIFAMPICIN HEPATITISThe Lancet, 1974